Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

Frank J. Accurso, Richard B. Moss, Robert W. Wilmott, Ran D. Anbar, Amy E. Schaberg, Todd A. Durham, Bonnie W. Ramsey, R. Ahrens, R. Anbar, D. Lindner, P. Anderson, A. Atlas, Y. Berthiaume, N. Beaudoin, D. Bisberg, P. Pock, S. Boas, D. Borowitz, J. Smith, A. S. ChidekelB. Chipps, J. F. Chmiel, B. Ksenich, J. P. Clancy, J. Colombo, D. Heimes, Cori L Daines, J. DeCelie-Germana, S. Galvin, R. Deterding, E. DiMango, H. Dorkin, A. Dozor, I. Gherson, J. Dunitz, M. Egan, J. Young, G. Elliott, J. Gadd, P. Fornos, M. Franco, D. Froh, R. Kelly, D. Geller, D. Cook, R. Gibson, A. Genatossio, G. Gong, G. Graff, K. Hardy, A. Robles, D. Hicks, M. Howenstine, L. Bendy, K. Jones, A. Gardner, J. Kanga, B. Owsley, J. Kreindler, C. Lapin, G. Drapeau, R. Lee, M. Dillard, T. Liou, K. S. McCoy, P. Olson, S. Millard, R. Moss, C. Dunn, Z. Davies, C. Nakamura, T. Brascia, S. Nasr, C. Oermann, L. Traplena, C. Prestidge, A. Prestridge, D. Delute, C. Ren, G. Retsch-Bogart, D. Towle, C. Barlow, S. Reyes, D. Roberts, V. Roberts, M. Rock, L. Makholm, R. Rubenstein, C. Kubrak, C. Murray, D. Schaeffer, E. DeLuca, M. Schechter, J. Peabody, D. Schellhase, P. Walker, C. Grece, M. Wall, A. Guzik, D. Weiner, A. Horn, D. B. Willey-Courand, V. Kociela, M. Woo, J. Wooldridge, L. Duan, P. Zeitlin, J. Zuckerman, R. Kennedy-DuDevoir

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Rationale: Intervention for cystic fibrosis lung disease early in its course has the potential to delay or prevent progressive changes that lead to irreversible airflow obstruction. Denufosol is a novel ion channel regulator designed to correct the ion transport defect and increase the overall mucociliary clearance in cystic fibrosis lung disease by increasing chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the airway epithelium independently of cystic fibrosis transmembrane conductance regulator genotype. Objectives: To evaluate the efficacy and safety of denufosol in patients with cystic fibrosis who had normal to mildly impaired lung function characteristic of early cystic fibrosis Methods: A total of 352 patients greater than or equal to 5 years old with cystic fibrosis who had FEV1 greater than or equal to 75% of predicted normal were randomized to receive inhaled denufosol, 60 mg, or placebo three times daily in a Phase 3, randomized, double-blind, placebo-controlled, 24-week trial. Measurements and Main Results: Main outcome measures included change in FEV1 from baseline to Week 24 endpoint and adverse events. Mean change from baseline to Week 24 endpoint in FEV1 (primary efficacy endpoint) was 0.048 L for denufosol (n = 178) and 0.003 L for placebo (n = 174; P = 0.047). No significant differences between groups were observed for secondary endpoints including exacerbation rate and other measures of lung function. Denufosol was well tolerated with adverse event and growth profiles similar to placebo. Conclusions: Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00357279).

Original languageEnglish (US)
Pages (from-to)627-634
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume183
Issue number5
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Cystic Fibrosis
Lung
Placebos
Lung Diseases
Mucociliary Clearance
Cystic Fibrosis Transmembrane Conductance Regulator
Ion Transport
Ion Channels
denufosol tetrasodium
Chlorides
Epithelium
Sodium
Genotype
Outcome Assessment (Health Care)
Clinical Trials
Safety
Growth

Keywords

  • Chloride channel activator
  • Early intervention
  • ENaC inhibition
  • Ion channel regulator
  • P2y receptor agonist

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Accurso, F. J., Moss, R. B., Wilmott, R. W., Anbar, R. D., Schaberg, A. E., Durham, T. A., ... Kennedy-DuDevoir, R. (2011). Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. American Journal of Respiratory and Critical Care Medicine, 183(5), 627-634. https://doi.org/10.1164/rccm.201008-1267OC

Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. / Accurso, Frank J.; Moss, Richard B.; Wilmott, Robert W.; Anbar, Ran D.; Schaberg, Amy E.; Durham, Todd A.; Ramsey, Bonnie W.; Ahrens, R.; Anbar, R.; Lindner, D.; Anderson, P.; Atlas, A.; Berthiaume, Y.; Beaudoin, N.; Bisberg, D.; Pock, P.; Boas, S.; Borowitz, D.; Smith, J.; Chidekel, A. S.; Chipps, B.; Chmiel, J. F.; Ksenich, B.; Clancy, J. P.; Colombo, J.; Heimes, D.; Daines, Cori L; DeCelie-Germana, J.; Galvin, S.; Deterding, R.; DiMango, E.; Dorkin, H.; Dozor, A.; Gherson, I.; Dunitz, J.; Egan, M.; Young, J.; Elliott, G.; Gadd, J.; Fornos, P.; Franco, M.; Froh, D.; Kelly, R.; Geller, D.; Cook, D.; Gibson, R.; Genatossio, A.; Gong, G.; Graff, G.; Hardy, K.; Robles, A.; Hicks, D.; Howenstine, M.; Bendy, L.; Jones, K.; Gardner, A.; Kanga, J.; Owsley, B.; Kreindler, J.; Lapin, C.; Drapeau, G.; Lee, R.; Dillard, M.; Liou, T.; McCoy, K. S.; Olson, P.; Millard, S.; Moss, R.; Dunn, C.; Davies, Z.; Nakamura, C.; Brascia, T.; Nasr, S.; Oermann, C.; Traplena, L.; Prestidge, C.; Prestridge, A.; Delute, D.; Ren, C.; Retsch-Bogart, G.; Towle, D.; Barlow, C.; Reyes, S.; Roberts, D.; Roberts, V.; Rock, M.; Makholm, L.; Rubenstein, R.; Kubrak, C.; Murray, C.; Schaeffer, D.; DeLuca, E.; Schechter, M.; Peabody, J.; Schellhase, D.; Walker, P.; Grece, C.; Wall, M.; Guzik, A.; Weiner, D.; Horn, A.; Willey-Courand, D. B.; Kociela, V.; Woo, M.; Wooldridge, J.; Duan, L.; Zeitlin, P.; Zuckerman, J.; Kennedy-DuDevoir, R.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 5, 01.03.2011, p. 627-634.

Research output: Contribution to journalArticle

Accurso, FJ, Moss, RB, Wilmott, RW, Anbar, RD, Schaberg, AE, Durham, TA, Ramsey, BW, Ahrens, R, Anbar, R, Lindner, D, Anderson, P, Atlas, A, Berthiaume, Y, Beaudoin, N, Bisberg, D, Pock, P, Boas, S, Borowitz, D, Smith, J, Chidekel, AS, Chipps, B, Chmiel, JF, Ksenich, B, Clancy, JP, Colombo, J, Heimes, D, Daines, CL, DeCelie-Germana, J, Galvin, S, Deterding, R, DiMango, E, Dorkin, H, Dozor, A, Gherson, I, Dunitz, J, Egan, M, Young, J, Elliott, G, Gadd, J, Fornos, P, Franco, M, Froh, D, Kelly, R, Geller, D, Cook, D, Gibson, R, Genatossio, A, Gong, G, Graff, G, Hardy, K, Robles, A, Hicks, D, Howenstine, M, Bendy, L, Jones, K, Gardner, A, Kanga, J, Owsley, B, Kreindler, J, Lapin, C, Drapeau, G, Lee, R, Dillard, M, Liou, T, McCoy, KS, Olson, P, Millard, S, Moss, R, Dunn, C, Davies, Z, Nakamura, C, Brascia, T, Nasr, S, Oermann, C, Traplena, L, Prestidge, C, Prestridge, A, Delute, D, Ren, C, Retsch-Bogart, G, Towle, D, Barlow, C, Reyes, S, Roberts, D, Roberts, V, Rock, M, Makholm, L, Rubenstein, R, Kubrak, C, Murray, C, Schaeffer, D, DeLuca, E, Schechter, M, Peabody, J, Schellhase, D, Walker, P, Grece, C, Wall, M, Guzik, A, Weiner, D, Horn, A, Willey-Courand, DB, Kociela, V, Woo, M, Wooldridge, J, Duan, L, Zeitlin, P, Zuckerman, J & Kennedy-DuDevoir, R 2011, 'Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function', American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 5, pp. 627-634. https://doi.org/10.1164/rccm.201008-1267OC
Accurso, Frank J. ; Moss, Richard B. ; Wilmott, Robert W. ; Anbar, Ran D. ; Schaberg, Amy E. ; Durham, Todd A. ; Ramsey, Bonnie W. ; Ahrens, R. ; Anbar, R. ; Lindner, D. ; Anderson, P. ; Atlas, A. ; Berthiaume, Y. ; Beaudoin, N. ; Bisberg, D. ; Pock, P. ; Boas, S. ; Borowitz, D. ; Smith, J. ; Chidekel, A. S. ; Chipps, B. ; Chmiel, J. F. ; Ksenich, B. ; Clancy, J. P. ; Colombo, J. ; Heimes, D. ; Daines, Cori L ; DeCelie-Germana, J. ; Galvin, S. ; Deterding, R. ; DiMango, E. ; Dorkin, H. ; Dozor, A. ; Gherson, I. ; Dunitz, J. ; Egan, M. ; Young, J. ; Elliott, G. ; Gadd, J. ; Fornos, P. ; Franco, M. ; Froh, D. ; Kelly, R. ; Geller, D. ; Cook, D. ; Gibson, R. ; Genatossio, A. ; Gong, G. ; Graff, G. ; Hardy, K. ; Robles, A. ; Hicks, D. ; Howenstine, M. ; Bendy, L. ; Jones, K. ; Gardner, A. ; Kanga, J. ; Owsley, B. ; Kreindler, J. ; Lapin, C. ; Drapeau, G. ; Lee, R. ; Dillard, M. ; Liou, T. ; McCoy, K. S. ; Olson, P. ; Millard, S. ; Moss, R. ; Dunn, C. ; Davies, Z. ; Nakamura, C. ; Brascia, T. ; Nasr, S. ; Oermann, C. ; Traplena, L. ; Prestidge, C. ; Prestridge, A. ; Delute, D. ; Ren, C. ; Retsch-Bogart, G. ; Towle, D. ; Barlow, C. ; Reyes, S. ; Roberts, D. ; Roberts, V. ; Rock, M. ; Makholm, L. ; Rubenstein, R. ; Kubrak, C. ; Murray, C. ; Schaeffer, D. ; DeLuca, E. ; Schechter, M. ; Peabody, J. ; Schellhase, D. ; Walker, P. ; Grece, C. ; Wall, M. ; Guzik, A. ; Weiner, D. ; Horn, A. ; Willey-Courand, D. B. ; Kociela, V. ; Woo, M. ; Wooldridge, J. ; Duan, L. ; Zeitlin, P. ; Zuckerman, J. ; Kennedy-DuDevoir, R. / Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. In: American Journal of Respiratory and Critical Care Medicine. 2011 ; Vol. 183, No. 5. pp. 627-634.
@article{a60d7dad15f44249ac643c3605f8ad6a,
title = "Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function",
abstract = "Rationale: Intervention for cystic fibrosis lung disease early in its course has the potential to delay or prevent progressive changes that lead to irreversible airflow obstruction. Denufosol is a novel ion channel regulator designed to correct the ion transport defect and increase the overall mucociliary clearance in cystic fibrosis lung disease by increasing chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the airway epithelium independently of cystic fibrosis transmembrane conductance regulator genotype. Objectives: To evaluate the efficacy and safety of denufosol in patients with cystic fibrosis who had normal to mildly impaired lung function characteristic of early cystic fibrosis Methods: A total of 352 patients greater than or equal to 5 years old with cystic fibrosis who had FEV1 greater than or equal to 75{\%} of predicted normal were randomized to receive inhaled denufosol, 60 mg, or placebo three times daily in a Phase 3, randomized, double-blind, placebo-controlled, 24-week trial. Measurements and Main Results: Main outcome measures included change in FEV1 from baseline to Week 24 endpoint and adverse events. Mean change from baseline to Week 24 endpoint in FEV1 (primary efficacy endpoint) was 0.048 L for denufosol (n = 178) and 0.003 L for placebo (n = 174; P = 0.047). No significant differences between groups were observed for secondary endpoints including exacerbation rate and other measures of lung function. Denufosol was well tolerated with adverse event and growth profiles similar to placebo. Conclusions: Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00357279).",
keywords = "Chloride channel activator, Early intervention, ENaC inhibition, Ion channel regulator, P2y receptor agonist",
author = "Accurso, {Frank J.} and Moss, {Richard B.} and Wilmott, {Robert W.} and Anbar, {Ran D.} and Schaberg, {Amy E.} and Durham, {Todd A.} and Ramsey, {Bonnie W.} and R. Ahrens and R. Anbar and D. Lindner and P. Anderson and A. Atlas and Y. Berthiaume and N. Beaudoin and D. Bisberg and P. Pock and S. Boas and D. Borowitz and J. Smith and Chidekel, {A. S.} and B. Chipps and Chmiel, {J. F.} and B. Ksenich and Clancy, {J. P.} and J. Colombo and D. Heimes and Daines, {Cori L} and J. DeCelie-Germana and S. Galvin and R. Deterding and E. DiMango and H. Dorkin and A. Dozor and I. Gherson and J. Dunitz and M. Egan and J. Young and G. Elliott and J. Gadd and P. Fornos and M. Franco and D. Froh and R. Kelly and D. Geller and D. Cook and R. Gibson and A. Genatossio and G. Gong and G. Graff and K. Hardy and A. Robles and D. Hicks and M. Howenstine and L. Bendy and K. Jones and A. Gardner and J. Kanga and B. Owsley and J. Kreindler and C. Lapin and G. Drapeau and R. Lee and M. Dillard and T. Liou and McCoy, {K. S.} and P. Olson and S. Millard and R. Moss and C. Dunn and Z. Davies and C. Nakamura and T. Brascia and S. Nasr and C. Oermann and L. Traplena and C. Prestidge and A. Prestridge and D. Delute and C. Ren and G. Retsch-Bogart and D. Towle and C. Barlow and S. Reyes and D. Roberts and V. Roberts and M. Rock and L. Makholm and R. Rubenstein and C. Kubrak and C. Murray and D. Schaeffer and E. DeLuca and M. Schechter and J. Peabody and D. Schellhase and P. Walker and C. Grece and M. Wall and A. Guzik and D. Weiner and A. Horn and Willey-Courand, {D. B.} and V. Kociela and M. Woo and J. Wooldridge and L. Duan and P. Zeitlin and J. Zuckerman and R. Kennedy-DuDevoir",
year = "2011",
month = "3",
day = "1",
doi = "10.1164/rccm.201008-1267OC",
language = "English (US)",
volume = "183",
pages = "627--634",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function

AU - Accurso, Frank J.

AU - Moss, Richard B.

AU - Wilmott, Robert W.

AU - Anbar, Ran D.

AU - Schaberg, Amy E.

AU - Durham, Todd A.

AU - Ramsey, Bonnie W.

AU - Ahrens, R.

AU - Anbar, R.

AU - Lindner, D.

AU - Anderson, P.

AU - Atlas, A.

AU - Berthiaume, Y.

AU - Beaudoin, N.

AU - Bisberg, D.

AU - Pock, P.

AU - Boas, S.

AU - Borowitz, D.

AU - Smith, J.

AU - Chidekel, A. S.

AU - Chipps, B.

AU - Chmiel, J. F.

AU - Ksenich, B.

AU - Clancy, J. P.

AU - Colombo, J.

AU - Heimes, D.

AU - Daines, Cori L

AU - DeCelie-Germana, J.

AU - Galvin, S.

AU - Deterding, R.

AU - DiMango, E.

AU - Dorkin, H.

AU - Dozor, A.

AU - Gherson, I.

AU - Dunitz, J.

AU - Egan, M.

AU - Young, J.

AU - Elliott, G.

AU - Gadd, J.

AU - Fornos, P.

AU - Franco, M.

AU - Froh, D.

AU - Kelly, R.

AU - Geller, D.

AU - Cook, D.

AU - Gibson, R.

AU - Genatossio, A.

AU - Gong, G.

AU - Graff, G.

AU - Hardy, K.

AU - Robles, A.

AU - Hicks, D.

AU - Howenstine, M.

AU - Bendy, L.

AU - Jones, K.

AU - Gardner, A.

AU - Kanga, J.

AU - Owsley, B.

AU - Kreindler, J.

AU - Lapin, C.

AU - Drapeau, G.

AU - Lee, R.

AU - Dillard, M.

AU - Liou, T.

AU - McCoy, K. S.

AU - Olson, P.

AU - Millard, S.

AU - Moss, R.

AU - Dunn, C.

AU - Davies, Z.

AU - Nakamura, C.

AU - Brascia, T.

AU - Nasr, S.

AU - Oermann, C.

AU - Traplena, L.

AU - Prestidge, C.

AU - Prestridge, A.

AU - Delute, D.

AU - Ren, C.

AU - Retsch-Bogart, G.

AU - Towle, D.

AU - Barlow, C.

AU - Reyes, S.

AU - Roberts, D.

AU - Roberts, V.

AU - Rock, M.

AU - Makholm, L.

AU - Rubenstein, R.

AU - Kubrak, C.

AU - Murray, C.

AU - Schaeffer, D.

AU - DeLuca, E.

AU - Schechter, M.

AU - Peabody, J.

AU - Schellhase, D.

AU - Walker, P.

AU - Grece, C.

AU - Wall, M.

AU - Guzik, A.

AU - Weiner, D.

AU - Horn, A.

AU - Willey-Courand, D. B.

AU - Kociela, V.

AU - Woo, M.

AU - Wooldridge, J.

AU - Duan, L.

AU - Zeitlin, P.

AU - Zuckerman, J.

AU - Kennedy-DuDevoir, R.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Rationale: Intervention for cystic fibrosis lung disease early in its course has the potential to delay or prevent progressive changes that lead to irreversible airflow obstruction. Denufosol is a novel ion channel regulator designed to correct the ion transport defect and increase the overall mucociliary clearance in cystic fibrosis lung disease by increasing chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the airway epithelium independently of cystic fibrosis transmembrane conductance regulator genotype. Objectives: To evaluate the efficacy and safety of denufosol in patients with cystic fibrosis who had normal to mildly impaired lung function characteristic of early cystic fibrosis Methods: A total of 352 patients greater than or equal to 5 years old with cystic fibrosis who had FEV1 greater than or equal to 75% of predicted normal were randomized to receive inhaled denufosol, 60 mg, or placebo three times daily in a Phase 3, randomized, double-blind, placebo-controlled, 24-week trial. Measurements and Main Results: Main outcome measures included change in FEV1 from baseline to Week 24 endpoint and adverse events. Mean change from baseline to Week 24 endpoint in FEV1 (primary efficacy endpoint) was 0.048 L for denufosol (n = 178) and 0.003 L for placebo (n = 174; P = 0.047). No significant differences between groups were observed for secondary endpoints including exacerbation rate and other measures of lung function. Denufosol was well tolerated with adverse event and growth profiles similar to placebo. Conclusions: Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00357279).

AB - Rationale: Intervention for cystic fibrosis lung disease early in its course has the potential to delay or prevent progressive changes that lead to irreversible airflow obstruction. Denufosol is a novel ion channel regulator designed to correct the ion transport defect and increase the overall mucociliary clearance in cystic fibrosis lung disease by increasing chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the airway epithelium independently of cystic fibrosis transmembrane conductance regulator genotype. Objectives: To evaluate the efficacy and safety of denufosol in patients with cystic fibrosis who had normal to mildly impaired lung function characteristic of early cystic fibrosis Methods: A total of 352 patients greater than or equal to 5 years old with cystic fibrosis who had FEV1 greater than or equal to 75% of predicted normal were randomized to receive inhaled denufosol, 60 mg, or placebo three times daily in a Phase 3, randomized, double-blind, placebo-controlled, 24-week trial. Measurements and Main Results: Main outcome measures included change in FEV1 from baseline to Week 24 endpoint and adverse events. Mean change from baseline to Week 24 endpoint in FEV1 (primary efficacy endpoint) was 0.048 L for denufosol (n = 178) and 0.003 L for placebo (n = 174; P = 0.047). No significant differences between groups were observed for secondary endpoints including exacerbation rate and other measures of lung function. Denufosol was well tolerated with adverse event and growth profiles similar to placebo. Conclusions: Denufosol improved lung function relative to placebo in cystic fibrosis patients with normal to mildly impaired lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00357279).

KW - Chloride channel activator

KW - Early intervention

KW - ENaC inhibition

KW - Ion channel regulator

KW - P2y receptor agonist

UR - http://www.scopus.com/inward/record.url?scp=79952211206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952211206&partnerID=8YFLogxK

U2 - 10.1164/rccm.201008-1267OC

DO - 10.1164/rccm.201008-1267OC

M3 - Article

C2 - 21169471

AN - SCOPUS:79952211206

VL - 183

SP - 627

EP - 634

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -